Gilder Gagnon Howe & Co’s Aurinia Pharmaceuticals AUPH Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-179,090	Closed	-$1.35M	–	247
2022 Q3	$1.35M	Sell	179,090 -876	-0.5%	-$7.58K	0.02%	188
2022 Q2	$1.81M	Sell	179,966 -17,969	-9%	-$201K	0.03%	179
2022 Q1	$2.45M	Buy	197,935 +2,652	+1%	+$41K	0.02%	215
2021 Q4	$4.47M	Buy	195,283 +3,969	+2%	+$94K	0.03%	225
2021 Q3	$4.23M	Buy	191,314 +749	+0.4%	+$11.9K	0.02%	261
2021 Q2	$2.47M	Buy	190,565 +5,740	+3%	+$73.1K	0.01%	295
2021 Q1	$2.4M	Buy	184,825 +4,575	+3%	+$66.4K	0.01%	272
2020 Q4	$2.49M	Buy	+180,250	New	+$2.62M	0.01%	245

Other funds holding AUPH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Gilder Gagnon Howe & Co's AUPH Position: Q4 2022 in Review

Gilder Gagnon Howe & Co sold out of Aurinia Pharmaceuticals (AUPH) in Q4 2022, closing a stake of 179,090 shares — an estimated $1.35M sold.

Gilder Gagnon Howe & Co first reported a position in AUPH in Q4 2020 and held it in 8 quarters. The position peaked at $4.47M in Q4 2021. 191 funds tracked by Wall St. Rank hold AUPH as of Q4 2022.

Gilder Gagnon Howe & Co reported no remaining Aurinia Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Gilder Gagnon Howe & Co sold 179,090 Aurinia Pharmaceuticals shares in Q4 2022, an estimated $1.35M.
Gilder Gagnon Howe & Co first reported a position in Aurinia Pharmaceuticals in Q4 2020 and held it in 8 quarters.
Gilder Gagnon Howe & Co's Aurinia Pharmaceuticals position peaked at $4.47M in Q4 2021.
191 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q4 2022.

Based on Gilder Gagnon Howe & Co's 13F filing for Q4 2022, filed 14 Feb 2023.